Works matching AU Giovannoni G

Results: 67

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.

Published in:

Acta Neurologica Scandinavica, 2013, v. 128, n. 6, p. e33, doi. 10.1111/ane.12151

By:

Kuhle, J.;
Malmeström, C.;
Axelsson, M.;
Plattner, K.;
Yaldizli, Ö.;
Derfuss, T.;
Giovannoni, G.;
Kappos, L.;
Lycke, J.

Publication type:

Article

Cerebrospinal fluid and urinary biomarkers in multiple sclerosis.

Published in:

Acta Neurologica Scandinavica, 2013, v. 128, n. 5, p. 321, doi. 10.1111/ane.12119

By:

Dobson, R.;
Topping, J.;
Davis, A.;
Thompson, E.;
Giovannoni, G.

Publication type:

Article

Seroprevalence of herpes simplex virus type 2 in multiple sclerosis.

Published in:

Acta Neurologica Scandinavica, 2006, v. 114, n. 6, p. 363, doi. 10.1111/j.1600-0404.2006.00677.x

By:

Hawkes, C. H.;
Giovannoni, G.;
Keir, G.;
Cunnington, M.;
Thompson, E. J.

Publication type:

Article

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary.

Published in:

Multiple Sclerosis Journal, 2021, v. 27, n. 7, p. 1006, doi. 10.1177/13524585211010070

By:

Schmierer, K;
Giovannoni, G

Publication type:

Article

Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.

Published in:

Multiple Sclerosis Journal, 2013, v. 19, n. 14, p. 1896, doi. 10.1177/1352458513485982

By:

Pryce, G;
Cabranes, A;
Fernández-Ruiz, J;
Bisogno, T;
Di Marzo, V;
Long, JZ;
Cravatt, BF;
Giovannoni, G;
Baker, D

Publication type:

Article

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.

Published in:

Multiple Sclerosis Journal, 2012, v. 18, n. 7, p. 932, doi. 10.1177/1352458511433302

By:

Giovannoni, G;
Southam, E;
Waubant, E

Publication type:

Article

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.

Published in:

Multiple Sclerosis Journal, 2011, v. 17, n. 11, p. 1333, doi. 10.1177/1352458511412654

By:

Farrell, RA;
Espasandin, M;
Lakdawala, N;
Creeke, PI;
Worthington, V;
Giovannoni, G

Publication type:

Article

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.

Published in:

Multiple Sclerosis Journal, 2011, v. 17, n. 5, p. 578, doi. 10.1177/1352458510391344

By:

Cook, S.;
Vermersch, P.;
Comi, G.;
Giovannoni, G.;
Rammohan, K.;
Rieckmann, P.;
Sørensen, P. Soelberg;
Hamlett, A.;
Miret, M.;
Weiner, J.;
Viglietta, V.;
Musch, B.;
Greenberg, S. J.

Publication type:

Article

HLA-DRB1*15, low infant sibling exposure, and multiple sclerosis gene-environment interaction.

Published in:

2010

By:

Ramagopalan SV;
Dyment DA;
Giovannoni G;
Sadovnick AD;
Ebers GC

Publication type:

Journal Article

Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis.

Published in:

2000

By:

Giovannoni, Gavin;
Morris, Patricia R.;
Keir, Geoffrey;
Giovannoni, G;
Morris, P R;
Keir, G

Publication type:

commentary

Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis.

Published in:

1996

By:

Giovannoni, G.;
Green, A.;
Keir, G.;
Thompson, E. J.

Publication type:

Letter

Neutralising antibodies to interferon β in multiple sclerosis.

Published in:

Journal of Neurology, 2007, v. 254, n. 7, p. 827, doi. 10.1007/s00415-006-0486-3

By:

Hartung, H.-P.;
Polman, C.;
Bertolotto, A.;
Deisenhammer, F.;
Giovannoni, G.;
Havrdova, E.;
Hemmer, B.;
Hillert, J.;
Kappos, L.;
Kieseier, B.;
Killestein, J.;
Malcus, C.;
Comabella, M.;
Pachner, A.;
Schellekens, H.;
Sellebjerg, F.;
Selmaj, K.;
Sorensen, P.

Publication type:

Article

Book Reviews.

Published in:

2003

By:

Giovannoni, G.;
Bristol, D.R.;
Griffin, N.

Publication type:

Book Review

Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis.

Published in:

Journal of Neurology, 2001, v. 248, n. 6, p. 487, doi. 10.1007/s004150170158

By:

Giovannoni, G.;
Miller, D.H.;
Losseff, N.A.;
Sailer, M.;
Lewellyn-Smith, N.;
Thompson, A.J.;
Thompson, E.J.

Publication type:

Article

Nitric oxide and headache: related, but how?

Published in:

2003

By:

Empl, M;
Giovannoni, G

Publication type:

Editorial

Book Reviews.

Published in:

1996

By:

Giovannoni, G

Publication type:

Book Review

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Published in:

2010

By:

Giovannoni, G.;
Comi, G.;
Cook, S.

Publication type:

Opinion

Vitamin D and multiple sclerosis hospital admissions in Scotland.

Published in:

QJM: An International Journal of Medicine, 2011, v. 104, n. 11, p. 1001, doi. 10.1093/qjmed/hcr101

By:

Disanto, G.;
Handel, A.E.;
Morahan, J.M.;
Deluca, G.C.;
Kimball, S.M.;
Hypponen, E.;
Giovannoni, G.;
Ebers, G.C.;
Ramagopalan, S.V.

Publication type:

Article

GLKs directly regulate carotenoid biosynthesis via interacting with GBFs in plants.

Published in:

New Phytologist, 2025, v. 246, n. 2, p. 645, doi. 10.1111/nph.20457

By:

Sun, Tianhu;
Hazra, Abhijit;
Lui, Andy;
Zeng, Shaohua;
Wang, Xin;
Rao, Sombir;
Owens, Lauren A.;
Fei, Zhangjun;
Zhao, Yunde;
Mazourek, Michael;
Giovannoni, James G.;
Li, Li

Publication type:

Article

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases.

Published in:

Clinical & Experimental Immunology, 2020, v. 202, n. 2, p. 149, doi. 10.1111/cei.13495

By:

Baker, D.;
Roberts, C. A. K.;
Pryce, G.;
Kang, A. S.;
Marta, M.;
Reyes, S.;
Schmierer, K.;
Giovannoni, G.;
Amor, S.

Publication type:

Article

Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?

Published in:

Clinical & Experimental Immunology, 2012, v. 167, n. 1, p. 1, doi. 10.1111/j.1365-2249.2011.04446.x

By:

Meier, U.-C.;
Giovannoni, G.;
Tzartos, J. S.;
Khan, G.

Publication type:

Article

Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis.

Published in:

Brain: A Journal of Neurology, 2008, v. 131, n. 7, p. 1736, doi. 10.1093/brain/awn119

By:

J. M. Anderson;
D. W. Hampton;
R. Patani;
G. Pryce;
R. A. Crowther;
R. Reynolds;
R. J. M. Franklin;
G. Giovannoni;
D. A. S. Compston;
D. Baker;
M. G. Spillantini;
S. Chandran

Publication type:

Article

Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity.

Published in:

2004

By:

Dale RC;
Church AJ;
Surtees RAH;
Lees AJ;
Adcock JE;
Harding B;
Neville BGR;
Giovannoni G

Publication type:

Journal Article

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Published in:

Brain: A Journal of Neurology, 2003, v. 126, n. 10, p. 2191

By:

G. Giovannoni;
G. Pryce;
M.L. Cuzner;
Z. Ahmed;
D. Baker;
D.J.R. Hankey;
S.J. Jackson;
J.L. Croxford;
J.M. Pocock;
C. Ledent;
A. Petzold;
A.J. Thompson

Publication type:

Article

Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.

Published in:

Brain: A Journal of Neurology, 2002, v. 125, n. 7, p. 1462, doi. 10.1093/brain/awf165

By:

Petzold, A.;
Eikelenboom, M. J.;
Gveric, D.;
Keir, G.;
Chapman, M.;
Lazeron, R. H. C.;
Cuzner, M. L.;
Polman, C. H.;
Uitdehaag, B. M. J.;
Thompson, E. J.;
Giovannoni, G.

Publication type:

Article

The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.

Published in:

2000

By:

Banati, R B;
Newcombe, J;
Gunn, R N;
Cagnin, A;
Turkheimer, F;
Heppner, F;
Price, G;
Wegner, F;
Giovannoni, G;
Miller, D H;
Perkin, G D;
Smith, T;
Hewson, A K;
Bydder, G;
Kreutzberg, G W;
Jones, T;
Cuzner, M L;
Myers, R

Publication type:

journal article

Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis.

Published in:

Brain: A Journal of Neurology, 1997, v. 120, n. 1, p. 1, doi. 10.1093/brain/120.1.1

By:

Giovannoni, G;
Lai, M;
Kidd, D;
Thorpe, J W;
Miller, D H;
Thompson, A J;
Keir, G;
Feldmann, M;
Thompson, E J

Publication type:

Article

EFNS guidelines on disease-specific CSF investigations.

Published in:

European Journal of Neurology, 2009, v. 16, n. 6, p. 760, doi. 10.1111/j.1468-1331.2009.02595.x

By:

Deisenhammer, F.;
Egg, R.;
Giovannoni, G.;
Hemmer, B.;
Petzold, A.;
Sellebjerg, F.;
Teunissen, C.;
Tumani, H.

Publication type:

Article

Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients.

Published in:

European Journal of Neurology, 2006, v. 13, n. 12, p. 1346, doi. 10.1111/j.1468-1331.2006.01509.x

By:

Rejdak, K.;
Empl, M.;
Giffin, N. J.;
Afridi, S. K.;
Petzold, A.;
Stelmasiak, Z.;
Thompson, E. J.;
Goadsby, P. J.;
Kaube, H.;
Giovannoni, G.

Publication type:

Article

Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force.

Published in:

European Journal of Neurology, 2006, v. 13, n. 9, p. 913, doi. 10.1111/j.1468-1331.2006.01493.x

By:

Deisenhammer, F.;
Bartos, A.;
Egg, R.;
Gilhus, N. E.;
Giovannoni, G.;
Rauer, S.;
Sellebjerg, F.

Publication type:

Article

Tournaments.

Published in:

2005

By:

Rejdak, K.;
Petzold, A.;
Chard, D.;
Griffin, C.;
Miszkiel, K.A.;
Davis, G.;
Rashid, W.;
Miller, D.H.;
Stelmasiak, Z.;
Keir, G.;
Thompson, E.J.;
Giovannoni, G.;
Vonck, K.;
Boon, P.;
Claeys, P.;
De Smedt, T.;
De Herdt, V.;
Van Dycke, A.;
Gossiaux, F.;
Vingerhoets, G.

Publication type:

Other

Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme.

Published in:

Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2019, v. 5, n. 4, p. 1, doi. 10.1177/2055217319893103

By:

Giovannoni, G.;
Brex, P. A.;
Dhiraj, D.;
Fullarton, J.;
Freddi, M.;
Rodgers-Gray, B.;
Schmierer, K.

Publication type:

Article

Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 2010, v. 16, n. 9, p. 1066, doi. 10.1177/1352458510375100

By:

Rejdak, K.;
Leary, S. M.;
Petzold, A.;
Thompson, A. J.;
Miller, D. H.;
Giovannoni, G.

Publication type:

Article

Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography.

Published in:

Multiple Sclerosis (13524585), 2009, v. 15, n. 7, p. 795, doi. 10.1177/1352458509104594

By:

Al-Izki, S.;
Pryce, G.;
Giovannoni, G.;
Baker, D.

Publication type:

Article

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Published in:

Multiple Sclerosis (13524585), 2009, v. 15, n. 2, p. 219

By:

Giovannoni, G.;
Barbarash, O.;
Casset-Semanaz, F.;
King, J.;
Metz, L.;
Pardo, G.;
Simsarian, J.;
Sørensen, P. S.;
Stubinski, B.

Publication type:

Article

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.

Published in:

Multiple Sclerosis (13524585), 2008, v. 14, n. 2, p. 212, doi. 10.1177/1352458507082066

By:

Farrell, R.;
Kapoor, R.;
Leary, S.;
Rudge, P.;
Thompson, A. J.;
Miller, D. H.;
Giovannoni, G.

Publication type:

Article

Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 2008, v. 14, n. 1, p. 59, doi. 10.1177/1352458507082061

By:

Rejdak, K.;
Petzold, A.;
Stelmasiak, Z.;
Giovannoni, G.

Publication type:

Article

Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis -- are we there yet?

Published in:

Multiple Sclerosis (13524585), 2007, v. 13, n. 9, p. 1083

By:

Amor1, S.;
Giovannoni, G.

Publication type:

Article

The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers.

Published in:

Multiple Sclerosis (13524585), 2006, v. 12, n. 3, p. 325, doi. 10.1191/135248505ms1277oa

By:

Petzold, A.;
Eikelenboom, M. J.;
Keir, G.;
Polman, C. H.;
Uitdehaag, B. M. J.;
Thompson, E. J.;
Giovannoni, G.

Publication type:

Article

Acute axonal damage predicts clinical outcome in patients with multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 2005, v. 11, n. 5, p. 532, doi. 10.1191/1352458505ms1218oa

By:

Lim, E.T.;
Sellebjerg, F.;
Jensen, C.V.;
Altmann, D.R.;
Grant, D.;
Keir, G.;
Thompson, E.J.;
Giovannoni, G.

Publication type:

Article

Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 2005, v. 11, n. 4, p. 492, doi. 10.1191/1352458505ms1187sr

By:

Lim, ET;
Berger, T;
Reindl, M;
Dalton, CM;
Fernando, K;
Keir, G;
Thompson, EJ;
Miller, DH;
Giovannoni, G

Publication type:

Article

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 2004, v. 10, n. 6, p. 713, doi. 10.1191/1352458504ms1107xx

By:

Deisenhammer, F.;
Giovannoni, G.

Publication type:

Article

Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 2004, v. 10, n. 3, p. 281, doi. 10.1191/1352458504ms1021sr

By:

Petzo, A;
Brassat, D;
Mas, P;
Flejdak, K;
Keir, G;
Giovannoni, G;
Thompson, EJ;
Clane, M.

Publication type:

Article

Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease.

Published in:

Multiple Sclerosis (13524585), 1999, v. 5, n. 5, p. 335, doi. 10.1191/135245899678846320

By:

Giovannoni, G.;
Silver, N.C.;
O'Riordan, J.;
Miller, R.F.;
Heales, S.J.R.;
Land, J.M.;
Elliot, M.;
Feldmann, M.;
Miller, D.H.;
Thompson, E.J.

Publication type:

Article

Are there any body fluid markers of brain atrophy in multiple sclerosis?

Published in:

Multiple Sclerosis (13524585), 1998, v. 4, n. 3, p. 138, doi. 10.1191/135245898678909303

By:

Giovannoni, G.;
Green, A.J.E.;
Thompson, E.J.

Publication type:

Article

The potential role of nitric oxide in multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 1998, v. 4, n. 3, p. 212, doi. 10.1191/135245898678909312

By:

Giovannoni, G.;
Heales, S.J.R.;
Land, J.M.;
Thompson, E.J.

Publication type:

Article

Urinary markers of disease activity in multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 1998, v. 4, n. 3, p. 247, doi. 10.1191/135245898678909321

By:

Giovannoni, G.;
Thompson, E.J.

Publication type:

Article

Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis.

Published in:

Multiple Sclerosis (13524585), 1998, v. 4, n. 1, p. 27, doi. 10.1191/135245898678909178

By:

Giovannoni, G.

Publication type:

Article

Lack of Serum Oligoclonal Antibody Responses to Chlamydophila pneumoniae in Multiple Sclerosis.

Published in:

European Neurology, 2005, v. 53, n. 2, p. 81, doi. 10.1159/000084933

By:

Chapman, M. D.;
Hartley, J. C.;
Furrows, S. J.;
Ridgeway, G. L.;
Thompson, E. J.;
Church, A. J.;
Candler, P. M.;
Giovannoni, G.

Publication type:

Article

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Published in:

2008

By:

Gani R;
Giovannoni G;
Bates D;
Kemball B;
Hughes S;
Kerrigan J;
Gani, Ray;
Giovannoni, Gavin;
Bates, David;
Kemball, Belinda;
Hughes, Steve;
Kerrigan, John

Publication type:

journal article